Daniel Loeb doesn't merely invest in change—he often creates it. From activist campaigns and event-driven investing to new positions in gold and crypto, here's a deep dive into Third Point's latest portfolio moves and what they may signal for investors.

Read entire article

ValueAct Capital doesn’t fight corporate wars in public — it quietly rewires companies from inside the boardroom. Discover the fund’s $5.9B 2026 portfolio, biggest stock bets, stealth activist strategy, and why Wall Street fears the calmest investors the most.

Read entire article

Bill Ackman is opening the gates to his investing empire—but is this IPO a golden ticket or a cleverly packaged trade-off? From NAV discounts to DIY replication, here’s the real audit behind the hype.

Read entire article

Fisher Investments doesn’t start with stocks—it starts with the world. With $387B under management, this macro-first powerhouse takes a very different approach to investing. Here’s what’s really going on under the hood.

Read entire article

When the Baker Bros. — biotech’s most famous hedge fund — start scooping up more shares of Madrigal Pharma (MDGL), you know something’s cooking. With Rezdiffra sales booming, losses shrinking, and Wall Street titans circling, the tune of this Madrigal might be worth humming 🎶.

Read entire article

Paul Tudor Jones is going heavy on small caps—and maybe prepping for AI-induced doom. With 1,350+ positions and an options playbook that could fill a library, what’s his real bet? And more importantly: should you follow? Read on, but don’t YOLO.

Read entire article

With a $72.7B AUM symphony, Paul Singer’s Elliott Investment Management conducts activist investing like a maestro — dissonance included. Here's why their sharp portfolio and sharper strategy deserve your attention (and maybe your applause). 🎻📈

Read entire article